Completed NA INTERVENTIONAL 2-arm NCT04486482

A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function

An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients With Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting

Sponsor: Kaleido Biosciences

Conditions Mild-to-Moderate COVID-19

Interventions KB109 + Self Supportive Care (SSC) Self Supportive Care (SSC) Alone

Updated 6 times since 2020 Last updated: Aug 12, 2021 Started: Jan 12, 2021 Primary completion: Mar 30, 2021 Completion: Mar 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Mild-to-Moderate COVID-19 and is currently completed. Kaleido Biosciences leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Sep 2021 — Jul 2024 [monthly]

Completed NA

Status: Recruiting → Completed
Mar 2021 — Sep 2021 [monthly]

Recruiting NA
Jan 2021 — Mar 2021 [monthly]

Recruiting NA

▶ Show 1 earlier version

Aug 2020 — Jan 2021 [monthly]

Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kaleido Biosciences

Data source: Kaleido Biosciences

For direct contact, visit the study record on ClinicalTrials.gov .

A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function

Status Flow

Change History

Eligibility Summary

Contact Information

Study Locations

Related Trials